Dabrafenib and Trametinib
About
Membership operator: AND
Therapies: 2
Therapies
Dabrafenib (tx:ncit:C82386)
Trametinib (tx:ncit:C77908)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (4) FDA (8) | BRAF p.V600E | Melanoma | Dabrafenib, Trametinib | |
| EMA (4) FDA (8) | BRAF p.V600K | Melanoma | Dabrafenib, Trametinib | |
| EMA (2) FDA (4) | BRAF p.V600E | Non-Small Cell Lung Cancer | Dabrafenib, Trametinib | |
| FDA (4) | BRAF p.V600E | Anaplastic Thyroid Cancer | Dabrafenib, Trametinib | |
| FDA (4) | BRAF p.V600E | Any solid tumor | Dabrafenib, Trametinib | |
| EMA (1) FDA (4) | BRAF p.V600E | Low-Grade Glioma | Dabrafenib, Trametinib | |
| EMA (2) | BRAF p.V600K | Non-Small Cell Lung Cancer | Dabrafenib, Trametinib | |
| EMA (1) | BRAF p.V600E | High-Grade Glioma | Dabrafenib, Trametinib | |
| EMA (1) | BRAF p.V600E | Differentiated Thyroid Gland Carcinoma | Dabrafenib, Trametinib |